Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

Scientific exchange · Dr. Chloé Fischer

25 Jan 2026 · In person · Dr. Chloé Fischer, Kyoto University Hospital · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0060—

Capture insight from this engagement

Location: Kyoto University Hospital
Therapeutic area: Oncology
Country: Japan
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Chemotherapy-free first line

Scientific content used

VTX core scientific deck v3.2
irAE management guide

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Scientific exchange with pathologist at Kyoto University Hospital. Discussed chemotherapy-free first line.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 3
Depth of exchange: 2
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0060

Audit history (1)

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
03 Sept 2026, 17:57 UTC	Update	GNGrace Nakamura	progress	— → Submitted	—	UI